Dipyridamole

cardiac valve replacement, Transient cerebral ischemia, Coronary Artery Disease (CAD) + 9 more
Treatment
5 FDA approvals
20 Active Studies for Dipyridamole

What is Dipyridamole

DipyridamoleThe Generic name of this drug
Treatment SummaryDipyridamole is a medication that prevents the body from absorbing and breaking down adenosine, a compound found in red blood cells and the walls of blood vessels. It also helps to increase the effectiveness of prostacyclin, a drug used to reduce the risk of blood clots.
Dipyridamoleis the brand name
image of different drug pills on a surface
Dipyridamole Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Dipyridamole
Dipyridamole
1980
98

Approved as Treatment by the FDA

Dipyridamole, also known as Dipyridamole, is approved by the FDA for 5 uses like Postoperative Thromboembolism and Stroke .
Postoperative Thromboembolism
Stroke
Used to treat Cerebrovascular Accident in combination with Acetylsalicylic acid
Transient Ischemic Attack (TIA)
Used to treat Transient Ischemic Attack in combination with Acetylsalicylic acid
previous stroke
Used to treat previous stroke in combination with Acetylsalicylic acid
cardiac valve replacement

Effectiveness

How Dipyridamole Affects PatientsDipyridamole is a drug used to widen blood vessels and prevent blood clots, which can occur when someone has certain heart or blood vessel disorders. It is often taken with other drugs such as warfarin to help prevent thrombosis. Dipyridamole can also help show how well the heart is working, help prevent strokes, and reduce the risk of blood clots when combined with aspirin.
How Dipyridamole works in the bodyDipyridamole works by blocking the breakdown of cAMP, an inhibitor of platelet activity. By increasing cAMP levels, Dipyridamole prevents arachidonic acid from leaving cell membranes, and reduces the activity of thromboxane A2. It also stimulates the release of prostacyclin, which further raises the cAMP levels in platelets and further inhibits platelet aggregation.

When to interrupt dosage

The measure of Dipyridamole is contingent upon the distinguished condition, including Thrombosis, prior stroke and Stroke. The amount of dosage will be found in the table below, contingent upon the technique of administration (e.g. Tablet, coated or Capsule).
Condition
Dosage
Administration
Ischemic Stroke
, 25.0 mg, 50.0 mg, 200.0 mg, 75.0 mg, 5.0 mg/mL, 100.0 mg, 150.0 mg
, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Injection, Injection - Intravenous, Intravenous, Solution, Solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral
Heart Valve Prosthesis
, 25.0 mg, 50.0 mg, 200.0 mg, 75.0 mg, 5.0 mg/mL, 100.0 mg, 150.0 mg
, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Injection, Injection - Intravenous, Intravenous, Solution, Solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral
Anti-platelet Therapy
, 25.0 mg, 50.0 mg, 200.0 mg, 75.0 mg, 5.0 mg/mL, 100.0 mg, 150.0 mg
, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Injection, Injection - Intravenous, Intravenous, Solution, Solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral
Diagnostic Imaging
, 25.0 mg, 50.0 mg, 200.0 mg, 75.0 mg, 5.0 mg/mL, 100.0 mg, 150.0 mg
, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Injection, Injection - Intravenous, Intravenous, Solution, Solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral
cardiac valve replacement
, 25.0 mg, 50.0 mg, 200.0 mg, 75.0 mg, 5.0 mg/mL, 100.0 mg, 150.0 mg
, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Injection, Injection - Intravenous, Intravenous, Solution, Solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral
previous stroke
, 25.0 mg, 50.0 mg, 200.0 mg, 75.0 mg, 5.0 mg/mL, 100.0 mg, 150.0 mg
, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Injection, Injection - Intravenous, Intravenous, Solution, Solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral
Stroke
, 25.0 mg, 50.0 mg, 200.0 mg, 75.0 mg, 5.0 mg/mL, 100.0 mg, 150.0 mg
, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Injection, Injection - Intravenous, Intravenous, Solution, Solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral
Transient Ischemic Attack (TIA)
, 25.0 mg, 50.0 mg, 200.0 mg, 75.0 mg, 5.0 mg/mL, 100.0 mg, 150.0 mg
, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Injection, Injection - Intravenous, Intravenous, Solution, Solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral
Coronary Artery Disease (CAD)
, 25.0 mg, 50.0 mg, 200.0 mg, 75.0 mg, 5.0 mg/mL, 100.0 mg, 150.0 mg
, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Injection, Injection - Intravenous, Intravenous, Solution, Solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral
Myocardial Perfusion Imaging
, 25.0 mg, 50.0 mg, 200.0 mg, 75.0 mg, 5.0 mg/mL, 100.0 mg, 150.0 mg
, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Injection, Injection - Intravenous, Intravenous, Solution, Solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral
Postoperative Thromboembolism
, 25.0 mg, 50.0 mg, 200.0 mg, 75.0 mg, 5.0 mg/mL, 100.0 mg, 150.0 mg
, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Injection, Injection - Intravenous, Intravenous, Solution, Solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral
Transient cerebral ischemia
, 25.0 mg, 50.0 mg, 200.0 mg, 75.0 mg, 5.0 mg/mL, 100.0 mg, 150.0 mg
, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Injection, Injection - Intravenous, Intravenous, Solution, Solution - Intravenous, Injection, solution, Injection, solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Tablet, extended release, Tablet, extended release - Oral

Warnings

Dipyridamole Contraindications
Condition
Risk Level
Notes
Pulse Frequency
Do Not Combine
High Grade Atrioventricular Block
Do Not Combine
active wheezing
Do Not Combine
There are 20 known major drug interactions with Dipyridamole.
Common Dipyridamole Drug Interactions
Drug Name
Risk Level
Description
Abrocitinib
Major
The risk or severity of bleeding and thrombocytopenia can be increased when Dipyridamole is combined with Abrocitinib.
Acebutolol
Major
Dipyridamole may increase the bradycardic activities of Acebutolol.
Albutrepenonacog alfa
Major
The therapeutic efficacy of Albutrepenonacog alfa can be decreased when used in combination with Dipyridamole.
Alprenolol
Major
Dipyridamole may increase the bradycardic activities of Alprenolol.
Alprostadil
Major
The risk or severity of hypotension and priapism can be increased when Dipyridamole is combined with Alprostadil.
Dipyridamole Toxicity & Overdose RiskLow blood pressure may be a temporary side effect of drug overdose, but if needed, a medication to increase blood pressure can be administered. In rats, the lowest toxic dose is greater than 6,000mg/kg and in dogs it is roughly 400mg/kg. The lethal dose for a rat is 8.4g/kg when taken orally.
image of a doctor in a lab doing drug, clinical research

Dipyridamole Novel Uses: Which Conditions Have a Clinical Trial Featuring Dipyridamole?

38 active studies are currently assessing the potential of Dipyridamole to reduce Postoperative Thromboembolism, Stroke and Thrombosis.
Condition
Clinical Trials
Trial Phases
Stroke
11 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Phase 3
cardiac valve replacement
0 Actively Recruiting
Diagnostic Imaging
0 Actively Recruiting
Anti-platelet Therapy
0 Actively Recruiting
Coronary Artery Disease (CAD)
1 Actively Recruiting
Not Applicable
Ischemic Stroke
1 Actively Recruiting
Not Applicable
Heart Valve Prosthesis
0 Actively Recruiting
Transient Ischemic Attack (TIA)
8 Actively Recruiting
Not Applicable, Phase 4
Postoperative Thromboembolism
0 Actively Recruiting
Transient cerebral ischemia
0 Actively Recruiting
Myocardial Perfusion Imaging
1 Actively Recruiting
Phase 1
previous stroke
0 Actively Recruiting

Dipyridamole Reviews: What are patients saying about Dipyridamole?

5Patient Review
1/26/2013
Dipyridamole for Transient Ischemic Attack
I constantly had really severe headaches.
4.7Patient Review
10/8/2013
Dipyridamole for Transient Ischemic Attack
migraines are the absolute worst. I get pain not just in my head, but also radiating down into my neck and sinuses, as well as across my eyes. Sometimes I even get tingling and weakness in my arms.
4.3Patient Review
6/9/2009
Dipyridamole for Obstruction of a Blood Vessel by a Blood Clot
I wake up early with a severe headache that affects my temples, eyes, nose, and neck. I also feel nauseous. Symptoms go away by 10 or 11 a.m., but it's really debilitating while it lasts.
4Patient Review
7/4/2010
Dipyridamole for Transient Ischemic Attack
I had a TIA and was ordered to take this medication twice daily. However, I have cut down to once a day because I can only remember to take it about two times per week.
3Patient Review
1/9/2008
Dipyridamole for Prevention of Blood Clots in the Brain
2.3Patient Review
5/6/2012
Dipyridamole for Transient Ischemic Attack
I experienced some headaches and muscle pain while using this medication. I also had difficulty breathing and nosebleeds.
1.3Patient Review
11/27/2007
Dipyridamole for Transient Ischemic Attack
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about dipyridamole

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is dipyridamole an anticoagulant or antiplatelet?

"Dipyridamole is an antiplatelet agent used to prevent strokes and other blood clotting complications. It is often used in combination with warfarin after mechanical valve replacement surgery."

Answered by AI

Does dipyridamole contain aspirin?

"The recommended dose of Aggrenox is 1 capsule twice a day, with each capsule containing 25 mg of aspirin and 200 mg of dipyridamole."

Answered by AI

What class of drug is dipyridamole?

"Aspirin and extended-release dipyridamole work together as antiplatelet agents to reduce the risk of stroke. By preventing excessive blood clotting, the combination of these drugs help patients who have had or are at risk of stroke."

Answered by AI

Is dipyridamole still available?

"Although Boehringer Ingelheim announced that it would be discontinuing both Persantine and its authorized generic, dipyridamole, it is expected that there will be enough Persantine in pharmacies to last through May 2016 and enough dipyridamole to last through August 2017."

Answered by AI

Clinical Trials for Dipyridamole

Have you considered Dipyridamole clinical trials? We made a collection of clinical trials featuring Dipyridamole, we think they might fit your search criteria.
Have you considered Dipyridamole clinical trials? We made a collection of clinical trials featuring Dipyridamole, we think they might fit your search criteria.
Have you considered Dipyridamole clinical trials? We made a collection of clinical trials featuring Dipyridamole, we think they might fit your search criteria.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top